Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned an average recommendation of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $63.00.

DFTX has been the subject of a number of recent analyst reports. Canaccord Genuity Group set a $64.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Bank of America began coverage on Definium Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price target on the stock. Needham & Company LLC lifted their price objective on shares of Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Stifel Nicolaus boosted their target price on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th.

Definium Therapeutics Price Performance

NASDAQ:DFTX opened at $38.09 on Wednesday. The company has a market cap of $5.12 billion, a P/E ratio of -11.10 and a beta of 2.23. Definium Therapeutics has a 52-week low of $8.77 and a 52-week high of $49.70. The stock’s 50-day simple moving average is $43.70 and its 200 day simple moving average is $29.59. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, sell-side analysts forecast that Definium Therapeutics will post -3.02 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In related news, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 67,119 shares of company stock worth $2,887,496. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several large investors have recently made changes to their positions in the company. Nykredit A S bought a new stake in Definium Therapeutics during the 2nd quarter valued at $45,000. Cerity Partners LLC increased its position in shares of Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after acquiring an additional 1,165 shares in the last quarter. Creative Planning raised its holdings in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after acquiring an additional 1,655 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its position in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.